trending Market Intelligence /marketintelligence/en/news-insights/trending/v2it97gO5VZ5qtwJRl9L5Q2 content esgSubNav
In This List

Bausch Health, Glenmark settle patent dispute over plaque psoriasis lotion

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Bausch Health, Glenmark settle patent dispute over plaque psoriasis lotion

Bausch Health Cos. Inc. and Mumbai, India-based pharmaceutical company Glenmark Pharmaceuticals Ltd. agreed to settle the intellectual property lawsuit regarding Bausch's plaque psoriasis treatment Bryhali.

Under the agreement, Glenmark will have nonexclusive rights to market a royalty-free generic version of the lotion effective 2026 or earlier under certain circumstances, subject to approval from the U.S. Food and Drug Administration.

Canada-based Bausch received tentative approval for Bryhali from the FDA in October 2018 to treat plaque psoriasis in adults.

Plaque psoriasis is the most common form of psoriasis, in which the skin is red and covered with silvery scales or patches.

As part of the settlement, Glenmark acknowledged Bausch's patents for the lotion. Final patent expiry on Bryhali Lotion is 2031.